Search

Author/Creator Ryan, Aileen

1. ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). (5th November 2018)

Authors:
Reardon, David; Kaley, Thomas; Dietrich, Jorg; Clarke, Jennifer; Dunn, Gavin; Lim, Michael; Cloughesy, Tim; Gan, Hui; Park, Andrew; Schwarzenberger, Paul; Ricciardi, Toni; Macri, Mary; Ryan, Aileen; Venhaus, Ralph
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 6
Page Start:
vi10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. (1st January 2021)

Authors:
Slingluff, Craig L.; Zarour, Hassane M.; Tawbi, Hussein Abdul-Hassan; Kirkwood, John M.; Postow, Michael A.; Friedlander, Philip; Devoe, Craig E.; Gaughan, Elizabeth M.; Mauldin, Ileana S.; Olson, Walter C.; Smith, Kelly T.; Macri, Mary J.; Ricciardi, Toni; Ryan, Aileen; Venhaus, Ralph; Wolchok, ...
Journal:
Oncoimmunology
Issue:
Volume 10:Number 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search